AbbVie stock holds near record levels after second-quarter results

AbbVie Inc. (ISIN US00287Y1091) reported second-quarter 2026 revenue of $15.42 billion and adjusted diluted EPS of $2.97, while reaffirming full-year 2026 guidance on 22 July 2026. The numbers keep AbbVie stock tied to the pace of immunology demand, especially Skyrizi and Rinvoq.

Revenue above $15 billion

In second-quarter 2026 results, AbbVie said total revenue reached $15.42 billion, up from $14.46 billion in the second quarter of 2025, a year-over-year increase of about 6.6%. Adjusted diluted EPS of $2.97 compared with $2.65 a year earlier, showing that earnings growth continued alongside sales growth.

The second-quarter mix matters because the company has spent the last several quarters replacing the lost Humira contribution with newer brands. That shift is visible in the reported pace of the immunology portfolio, which remained the main growth engine in the period.

Guidance stayed unchanged

AbbVie kept its 2026 outlook in place on 22 July 2026, including adjusted diluted EPS guidance of $12.09 to $12.29 and total revenue guidance of $60.5 billion to $61.0 billion. That gives the market a simple yardstick: second-quarter revenue of $15.42 billion was enough to support the full-year range without forcing an upgrade.

For investors, the comparison that stands out is the combination of 6.6% year-over-year revenue growth and a 12.1% rise in adjusted EPS in the same quarter. The operating message is that AbbVie is still converting sales momentum into earnings growth while the Humira decline is further behind it.

Skyrizi and Rinvoq

AbbVie said Skyrizi and Rinvoq remained central to the quarter, with both products continuing to offset older portfolio pressure. The company has repeatedly framed these two medicines as the main drivers of its post-Humira revenue base, and the second-quarter 2026 figures reinforce that strategy.

That product concentration is useful for reading the stock because it reduces the story to one question: can immunology keep growing fast enough to hold the company's full-year targets? The latest quarter suggests the answer is still yes, at least at the current pace.

Market view on AbbVie stock

AbbVie stock can be read through a simple pair of numbers on 22 July 2026: second-quarter revenue of $15.42 billion and adjusted EPS of $2.97. If the company continues to deliver growth close to those levels, the guidance range for 2026 remains the main reference point rather than a new surprise.

The share price line would normally sit beside those operating figures, but in this article the dated market anchor is the earnings release itself and the full-year guidance range. That keeps the focus on what moved the valuation case most directly: earnings power and revenue traction.

Immunology drives the quarter

Skyrizi and Rinvoq are the representative products that matter most here because they carry the company's growth narrative beyond Humira. In second-quarter 2026, AbbVie again used those brands to show that its portfolio transition is still producing measurable revenue and profit support.

Guidance and valuation

AbbVie stock closed the latest evidence set on 22 July 2026 with a second-quarter print of $15.42 billion in revenue, adjusted EPS of $2.97, and a 2026 EPS guide of $12.09 to $12.29. That combination leaves the stock tied to execution rather than speculation, with the guidance range acting as the clearest benchmark for the rest of the year.